Rock Creek Pharmaceuticals Inc. (fka RCPIQ)

[thefamilyman]

From the PR - "Megha Verma of the Roskamp Institute delivered the poster presentation titled, "Anti-Inflammatory and Amyloid Beta Lowering Properties of Anatabine in a Transgenic Mouse Model of Alzheimer's Disease", in which scientists reported that anatabine treated Alzheimer's mice retained their memory and learning compared to the untreated Alzheimer's mice."

So the previous peer reviewed study showed that anatabine inhibited the plaque formation found in the brains of patients afflicted with alzheimers disease. And now they have proven that inhibiting the plaque formation does correlate with improved cognitive function! Incidentally, the studies with bexarotene appear to confirm this plaque/memory/cognitive function relationship. I think the official results of the on-going human study being conducted by Roskamp are probably still months away. But that study could be a game changer for the treatment of alzheimers disease. If I had someone close to me with the disease, they would be taking at least 9 pills a day. As I recall, 9 is the dosage being taken by the current study participants.